Drug Trial Radar · NCT02668172
Pasireotide LAR and Pegvisomant Study in Acromegaly
Last checked: Nov 20, 2026Latest source record: Aug 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Actual
Start
Aug 2015
Primary completion
Mar 2017
Study completion Jun 2017
Sponsor
- Lead sponsor
- Erasmus Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis
- First posted
- Jan 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the efficacy of Pasireotide Long Acting Release (LAR) alone and in combination with weekly Pegvisomant (PEGV) in acromegaIy patients previously controlled with combination treatment of long-acting Somatostatin analogs (LA-SSAs) and PEGV.
Conditions
- Acromegaly
Interventions
Pasireotide LAR 60 mgDrug
as mono-therapy or in combination with pegvisomant
PegvisomantDrug
only in combination with pasireotide LAR
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients with normalized IGF1 levels at 24 weeks in the pasireotide LAR monotherapy group and in the pasireotide LAR combined with pegvisomant groupTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Erasmus Medical Center
Rotterdam, South Holland, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.